CytoDyn Inc. (CYDY) EPS Estimated At $-0.05

CytoDyn Inc. (OTCMKTS:CYDY) Logo
Investors sentiment is 1 in 2018 Q4. Its the same as in 2018Q3. It is flat, as 0 investors sold CytoDyn Inc. shares while 1 reduced holdings. only 1 funds opened positions while 0 raised stakes. 575,200 shares or 55.17% more from 370,700 shares in 2018Q3 were reported.
Interocean Cap Limited Company holds 0.02% or 334,700 shares in its portfolio. Diversified Trust Communications holds 0.01% of its portfolio in CytoDyn Inc. (OTCMKTS:CYDY) for 225,500 shares. Inverness Counsel Limited Liability Corporation Ny has 0% invested in CytoDyn Inc. (OTCMKTS:CYDY) for 15,000 shares.

Analysts expect CytoDyn Inc. (OTCMKTS:CYDY) to report $-0.05 EPS on April, 8. The stock decreased 3.85% or $0.02 during the last trading session, reaching $0.5. About 839,413 shares traded or 92.23% up from the average. CytoDyn Inc. (OTCMKTS:CYDY) has 0.00% since March 17, 2018 and is . It has underperformed by 4.37% the S&P500.

CytoDyn Inc., a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus infection. The company has market cap of $152.08 million. The Company’s lead product under development for HIV infection include PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease. It currently has negative earnings.

More notable recent CytoDyn Inc. (OTCMKTS:CYDY) news were published by: Seekingalpha.com which released: “CytoDyn Is Gearing Up For A BLA Filing For Combo HIV Treatment – Seeking Alpha” on December 31, 2018, also Seekingalpha.com with their article: “CytoDyn launches study of PRO 140 in TNBC – Seeking Alpha” published on November 26, 2018, Seekingalpha.com published: “CytoDyn announces strategy to complete development of ProstaGene gene-based prostate cancer prognostic test – Seeking Alpha” on October 09, 2018. More interesting news about CytoDyn Inc. (OTCMKTS:CYDY) were released by: Seekingalpha.com and their article: “CytoDyn Makes Huge Stride For HIV Patients, Now Acts As A Potential Acquisition Target – Seeking Alpha” published on February 21, 2018 as well as Seekingalpha.com‘s news article titled: “CytoDyn Is Worth A Look Before Phase 3 HIV Data – Seeking Alpha” with publication date: November 20, 2017.

CytoDyn Inc. (OTCMKTS:CYDY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.